We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urinary Biomarkers Link Chronic Kidney Disease to Mitochondrial Dysfunction

By LabMedica International staff writers
Posted on 24 Oct 2013
An in-depth metabolomic study found that patients with chronic kidney disease (CKD) expressed a group of 13 biomarker metabolites that differentiated them from normal, healthy individuals. More...


The primary causes of CKD are high blood pressure and diabetes, and rates of both syndromes have risen sharply in the last decade, particularly among people aged 65 and older. The number of Americans with CKD is estimated to be more than 26 million.

Investigators at the University of California, San Diego (USA) and the biomedical company ClinMet (San Diego, CA, USA) collaborated in a study to identify reliable biomarkers in the urine of patients with CKD. The study was carried out using ClinMet's proprietary clinical metabolomics analysis platform.

Gas chromatography-mass spectrometry was used to quantify 94 metabolites in the urine of 193 patients with diabetes mellitus (DM) and CKD (DM+CKD), in patients with DM without CKD (DM–CKD), and in healthy controls. Results revealed that compared with levels in healthy controls, 13 metabolites were significantly reduced in the DM+CKD cohorts, and 12 of the 13 remained significant when compared with the DM–CKD cohort. Many of the differentially expressed metabolites were water-soluble organic anions.

Analysis of bioinformatics data indicated that 12 of the 13 differentially expressed metabolites were linked to mitochondrial metabolism and suggested the possibility of global suppression of mitochondrial activity in diabetic kidney disease. Supporting this analysis, human diabetic kidney sections were found to express less mitochondrial protein. Urine exosomes from patients with diabetes and CKD had less mitochondrial DNA, and kidney tissues from patients with diabetic kidney disease had lower gene expression of PGC1alpha (a master regulator of mitochondrial synthesis).

"It is clear from this study that urine- and plasma-based metabolomics can be a rich source of biomarkers for understanding and treating diabetic kidney disease and possibly for related cardiovascular complications," said first author Dr. Kumar Sharma, professor of medicine at the University of California, San Diego. "This approach also offers direct insights into biochemical pathways linked to kidney dysfunction. The urine metabolites can indicate the underlying function of the kidney at a biochemical and intracellular level, and are well conserved compared to many cell-based and protein measurements. Urine metabolomics also offers an opportunity to gauge effects of new treatments which will be an advantage to guide precision medicine."

The study was published in the October 10, 2013, online edition of the Journal of the American Society of Nephrology.

Related Links:

University of California, San Diego
ClinMet



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.